Trials / Completed
CompletedNCT04840992
Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation
A Randomized, Double-blind, Placebo-Controlled Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of Ad5-nCoV for Inhalation in Adults 18 Years of Age and Older
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 840 (actual)
- Sponsor
- CanSino Biologics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This study is a randomized, double-blind, placebo-controlled I/II clinical trial, in order to evaluate the safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation in adults 18 years of Age and Older.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation | Aerogen Solo |
| BIOLOGICAL | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) | Intramuscular administration |
| BIOLOGICAL | Placebo for Inhalation | Aerogen Solo |
| BIOLOGICAL | Placebo | Intramuscular administration |
Timeline
- Start date
- 2021-04-21
- Primary completion
- 2022-07-08
- Completion
- 2022-08-09
- First posted
- 2021-04-12
- Last updated
- 2023-02-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04840992. Inclusion in this directory is not an endorsement.